Evidence map›Paper›PMID 41105225›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Preclinical evaluation of DOTAGA.Glu.(FAPI)

Adrianna Bilinska, Naveen Kumar, Silvano Gnesin, Tilman Läppchen, Elena Menéndez, Marcel Martin, Frank Rösch, Axel Rominger, Eleni Gourni

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adrianna BilinskaDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Naveen KumarDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Silvano GnesinInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Tilman LäppchenDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Elena MenéndezDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Marcel MartinDepartment of Chemistry-TRIGA site, Johannes Gutenberg-University Mainz, Mainz, Germany.
Frank RöschDepartment of Chemistry-TRIGA site, Johannes Gutenberg-University Mainz, Mainz, Germany.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland.
Eleni GourniDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, Switzerland. eleni.gourni@insel.ch.ORCID 0000-0003-2198-382X

Funding

HORIZON EUROPE European Research Council No 101073231
6 · The paper itself

Abstract

purposeThis study aims to assess DOTAGA.Glu.(FAPI)

methodsDOTAGA.Glu.(FAPI)

resultsAll radioligands achievied > 98% radiochemical purity, demonstrating high FAP affinity (K

conclusionThese results support the potential clinical translation of DOTAGA.Glu.(FAPI)

Indexed as

LutetiumRadioisotopesTheranostic NanomedicineAnimalsGallium RadioisotopesHumansMaleMiceRadiometryRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyTissue DistributionGallium RadioisotopesLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsDimeric FAP inhibitorsDosimetryFAPGallium-68Lutetium-177Terbium-161

Identifiers

PMID41105225
PMCPMC12860872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.